October 12, 2020 Comments Off on InfaCare Pharmaceutical Corp. Investment Losses Blog, Current Investigations

InfaCare Pharmaceutical Corp. Investment Losses

InfaCare Pharmaceutical Corp. Investment Losses, featured by top securities fraud attorneys, The White Law Group

Concerned about your investment in InfaCare Pharmaceutical Corp.? 

Are you concerned about your investment losses in InfaCare Pharmaceutical Corp.? If so, the securities attorneys at The White Law Group may be able to help you by filing a FINRA Dispute Resolution claim against the brokerage firm that sold you the investment.

InfaCare Pharmaceutical Corporation is a specialty pharmaceutical company focused on development and commercialization of proprietary pharmaceuticals for neonatal and pediatric patient populations, according to Bloomberg. In September 2017, generic drug manufacturer Mallinckrodt reportedly acquired InfaCare Pharma for an upfront payment of $80 million and up to $345 million in regulatory and sales milestones payments, according to Pharma’s Almanac. 

Unfortunately for investors, Mallinckrodt filed for Chapter 11 bankruptcy protection October 12, 2020 as part of a large settlement with authorities over its role in the U.S. opioid epidemic, according to UPI.com.

The company has reportedly restructured debts to cope with billions of dollars in potential legal liabilities, as state and federal authorities sue to retrieve tax dollars that were spent on the health crisis.

Infacare Pharmaceutical Corp.  filed a form D to raise capital from investors in 2017, according to filings with the SEC. The total offering amount was purportedly $11,000,000.

Filing a Complaint against your Brokerage Firm

The White Law Group is investigating the liability that FINRA registered brokerage firms may have for improperly recommending high-risk investments to investors.

The problem with pharmaceutical and biotech investments such as Infacare Pharmaceutical Corp. is that they typically involve a high degree of risk. The research and development process for pharma companies often involves costly and lengthy testing trials that yield specific data. If the expected data or end points are not met, that could be bad news for investors.

Broker dealers are required to perform adequate due diligence on any investment they recommend and to ensure that all recommendations are suitable for the investor. Firms that fail to do so, may be held responsible for any losses in a FINRA arbitration claim.

If you have concerns regarding investment losses in InfaCare Pharmaceutical Corp., please call the securities attorneys at The White Law Group for a free consultation at 888-637-5510.

The White Law Group, LLC is a national securities fraud, securities arbitration, investor protection, and securities regulation/compliance law firm with offices in Chicago, Illinois and Franklin, Tennessee.

For more information on The White Law Group and its representation of investors in FINRA arbitration claims, visit https://www.whitesecuritieslaw.com.

 

 

 

Comments are closed.